Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
American ginseng + salvia miltiorrhiza is a traditional Chinese medicine (TCM) combination therapy formulated as an acupoint application patch. Developed by the Dongfang Hospital of Beijing University of Traditional Chinese Medicine, this combination leverages the 'Qi-tonifying' properties of American ginseng (*Panax quinquefolius*) and the 'blood-activating' properties of *Salvia miltiorrhiza* (Danshen). The therapy is primarily investigated as an adjunctive treatment for patients with acute myocardial infarction (AMI) who have undergone percutaneous coronary intervention (PCI). The mechanism involves the synergistic action of ginsenosides and tanshinones to improve left ventricular systolic function, alleviate angina symptoms, and modulate serologic markers of myocardial injury and inflammation. It is administered topically to specific acupoints to enhance recovery and reduce the incidence of major adverse cardiovascular events (MACE).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on american ginseng + salvia miltiorrhiza.